ArticleApplied biochemistry and biotechnology2026
Zinc Oxide Nanoparticles Functionalized with Ascorbic Acid and Conjugated with Chitosan Change Apoptotic Gene Expression in Gastric Adenocarcinoma Cell Line.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Zinc oxide-bacteriophage synergistic combination for dual-mode antibacterial activity against multidrug-resistant Escherichia coli.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer poses a significant global health challenge, with current treatment options like chemotherapy often resulting in toxicity to healthy cells. In this context, nanomedicine emerges as a promising strategy to enhance drug delivery and minimize adverse effects. This study focuses on developing Zinc oxide nanoparticles (ZnO-NPs) that are functionalized with ascorbic acid and conjugated with chitosan (ZnO@AsA/CS) to improve their efficacy and cellular uptake for targeting gastric adenocarcinoma cells (AGS). The ZnO-NPs were synthesized and modified to form ZnO@AsA/CS. Various characterization techniques, including X-ray diffraction (XRD), dynamic light scattering (DLS), Fourier-transform infrared spectroscopy (FTIR), polydispersity index (PDI), scanning electron microscopy (SEM), and transmission electron microscopy (TEM), were utilized to assess their properties. The cytotoxic effects of the nanoparticles for AGS and HGF-1 normal cells were evaluated through MTT assays. For AGS cells, lactate dehydrogenase (LDH) assays were conducted to examine cell membrane integrity. Additionally, the activity of Caspase-3, Caspase-8, and Caspase-9 was analyzed to explore apoptotic pathways. The generation of reactive oxygen species was measured using DCFH-DA staining, and the expression of apoptotic markers was analyzed via quantitative reverse transcription polymerase chain reaction (qRT-PCR). The characterization process revealed that the ZnO@AsA/CS nanoparticles had a uniform size distribution, averaging between 100 to 200 nm. MTT assay results indicated a dose-dependent reduction in AGS cell viability, with an IC
Indexed as
Identifiers
41222772What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.